Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice

British Journal of Pharmacology

Volumn 164, Issue 8, 2011, Pages 1929-1938

  Fiorucci, Stefano ^a   Mencarelli, Andrea ^a   Cipriani, Sabrina ^a   Renga, Barbara ^a   Palladino, Giuseppe ^a   Santucci, Luca ^b   Distrutti, Eleonora ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Acetyl salicylic acid; bile acids; cystathionine lyase; farnesoid X receptor; hydrogen sulphide; nitric oxide; non steroidal anti inflammatory drugs; nuclear receptors

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ACETYLSALICYLIC ACID; CHENODEOXYCHOLIC ACID; CYSTATHIONINE GAMMA LYASE; DICLOFENAC; FARNESOID X RECEPTOR; HYDROGEN SULFIDE; INDOMETACIN; KETOPROFEN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPARGYLGLYCINE; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG MECHANISM; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN TISSUE; INJURY SEVERITY; INTESTINE INJURY; INTESTINE MUCOSA; MOUSE; MOUSE STRAIN; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH MUCOSA INJURY; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTRIC MUCOSA; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; PEROXIDASE; POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81855228908     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01481.x     Document Type: Article

References (28)

1. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al,.; ACCF/ACG/AHA (2010). ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 105: 2533-2549.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al,. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817.
4. Fiorucci S, (2009). Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. Gastroenterol Clin North Am 38: 315-332.
5. 2S-releasing NSAIDs. Inflamm Allergy Drug Targets 10: 133-140.
6. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, Orlandi S, et al,. (2005). Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 129: 1210-1224. (Pubitemid 41446861)
7. 2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 39: 1043-1051. (Pubitemid 350131544)
8. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A, (2010). Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 49: 171-185.
9. Fitzgerald GA, (2004). Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711.
10. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, et al,. (2007). Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 25: 1211-1222. (Pubitemid 46650300)
11. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al,. (2005). Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225.
12. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, et al,. (2008). Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 135: 1517-1525.
13. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al,. (1995). Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492.
14. Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, et al,. (2008). FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 77: 169-177. (Pubitemid 351195146)
15. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al,. (1999). Identification of a nuclear receptor for bile acids. Science 284: 1362-1365. (Pubitemid 29289663)
16. Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, et al,. (2009). Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 328: 469-477.
17. Ogasawara Y, Ishii K, Tanabe S, (2002). Enzymatic assay of gamma-cystathionase activity using pyruvate oxidase-peroxidase sequential reaction. J Biochem Biophys Methods 51: 139-150. (Pubitemid 34406448)
18. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al,. (1999). Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368. (Pubitemid 29289664)
19. Pusztaszeri MP, Genta RM, Cryer BL, (2007). Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations. Nat Clin Pract Gastroenterol Hepatol 4: 442-453. (Pubitemid 47208894)
20. Renga B, Mencarelli A, Migliorati M, Cipriani S, Distrutti E, Fiorucci S, (2009). Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World J Gastroenterol 15: 2097-2108.
21. Reuter BK, Davies NM, Wallace JL, (1997). Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: 109-117. (Pubitemid 27008992)
22. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ, (2000). Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744.
23. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S, (2009). The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183: 6251-6261.
24. Wallace JL, (2007). Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci 28: 501-550.
25. Wallace JL, (2008). Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88: 1547-1565.
26. Wallace JL, Caliendo G, Santagada V, Cirino G, (2010). Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 159: 1236-1246.
27. Wang H, Chen J, Hollister K, Sowers LC, Forman BM, (1999). Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543-553. (Pubitemid 29268438)
28. Wolfe MM, Lichtenstein DR, Singh G, (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899. (Pubitemid 29272670)